Recherche

Publications

Publications de 2011

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S; for the German PTLD Study Group; the European PTLD Network.

Lancet Oncol. 2011 Dec 13.

Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis.

Mohty D, Pibarot P, Dumesnil JG, Darodes N, Lavergne D, Echahidi N, Virot P, Bordessoule D, Jaccard A.
Arch Cardiovasc Dis. 2011. 104 (12): 611-8.

Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study.

Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P, Thomas X, Lepretre S, Huguet F, Vey N, Escoffre-Barbe M, Tavernier E, Reman O, Fegueux N, Turlure P, Rousselot P, Cahn JY, Lheritier V, Chalandon Y, Béné MC, Macintyre E, Dombret H, Ifrah N; Group for Research on Adult Acute Lymphoblastic Leukemia.

Blood. 2011. 118 (19) :5099-107.
http://www.ncbi.nlm.nih.gov/pubmed/21835957

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators. Eur J Haematol. 2011 Oct;87(4):338-48.

Bellanger C, Dubanet L, Lise MC, Fauchais AL, Bordessoule D, Jauberteau MO, Troutaud D.

PLoS One. 2011;6(11):e27213.
http://www.ncbi.nlm.nih.gov/pubmed/22076137

Treatment with Lenalidomide does not appear to increase the risk of leukemia progression in lower risk myelodysplastic syndrome with 5q deletion. A comparative analysis by the GFM.

Ades L, Lebras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Guerci Bresler A, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P.

Haematologica. 2011 Oct 11.
http://www.ncbi.nlm.nih.gov/pubmed/21993675

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.

Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant J, Bordessoule D, Guidet B, Azoulay E, Rondeau E, Mira J, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P; on behalf of the French Thrombotic Microangiopathies Reference Center.

Crit Care Med. 2011 Sep 15.
http://www.ncbi.nlm.nih.gov/pubmed/21926591

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases.

Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, Bordessoule D, Stamatoullas A, Castaigne S, Terré C, Eclache V, Fenaux P, Adès L.

Leuk Res. 2011. 35(7):863-7
http://www.ncbi.nlm.nih.gov/pubmed/21396711

Extranodal natural killer/T-cell lymphoma: advances in the management.

Jaccard A, Hermine O.

Curr Opin Oncol. 2011 Jul 7.
http://www.ncbi.nlm.nih.gov/pubmed/21743325

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.

Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, Gardin C, Thomas X, Turlure P, Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C.
Leukemia. 2011 Jul 15.
http://www.ncbi.nlm.nih.gov/pubmed/21760594

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F.

Leuk Res. 2011. 35(11):1530-3.
http://www.ncbi.nlm.nih.gov/pubmed/21803419

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.

Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terré C, Fenaux P, Castaigne S, Dombret H, Boissel N; for the Acute Leukemia French Association (ALFA).
Haematologica. 2011. 96 (6):837-844.
http://www.ncbi.nlm.nih.gov/pubmed/21459791

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study.

Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, Filanovsky K, Cornillet-Lefebvre P, Luquet I, Lode L, Richebourg S, Blanchet O, Gachard N, Vey N, Ifrah N, Milpied N, Harousseau JL, Bene MC, Mohty M, Delaunay J.

Leukemia. 2011. 25(6):939-44.
http://www.ncbi.nlm.nih.gov/pubmed/21331073

Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations.

Ducamp S, Kannengiesser C, Touati M, Garçon L, Guerci-Bresler A, Guichard JF, Vermylen C, Dochir J, Poirel HA, Fouyssac F, Mansuy L, Leroux G, Tertian G, Girot R, Heimpel H, Matthes T, Talbi N, Deybach JC, Beaumont C, Puy H, Grandchamp B.

Hum Mutat. 2011. 32(6):590-7.
http://www.ncbi.nlm.nih.gov/pubmed/21309041

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-The GFM experience.

Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L.

Leuk Res. 2011. 35(11):1444-8.
http://www.ncbi.nlm.nih.gov/pubmed/21715006

Le coeur du métier de soignant en hématologie.

Bauchetet C, Bordessoule D, Casassus P, Ceccaldi J, Cheminant M, Bastard C, Colombat P, Damotte D, Fiat E, Jaulmes D, Jouet JP, Malak S, Margueritte G, Morin S, Poloméni A, Rochant H, Sotto JJ, Zandecki M, Zittoun R.

Hématologie. 17 (3) : 243-7.

Phospholipase A2 receptors in human leukemic blasts.

Amin R, Fiancette R, Bordessoule D, Turlure P, Guerin E, Trimoreau F, Denizot Y.

Leuk Lymphoma. 2011. 52(5):908-9.
http://www.ncbi.nlm.nih.gov/pubmed/21271860

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; for the Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators.

Lancet Oncol. 2011. 12(5):460-468.
http://www.ncbi.nlm.nih.gov/pubmed/21482186

A GEIL flow cytometry consensus proposal for quantification of plasma cells: Application to differential diagnosis between MGUS and myeloma.

Frébet E, Abraham J, Geneviève F, Lepelley P, Daliphard S, Bardet V, Amsellem S, Guy J, Mullier F, Durrieu F, Venon MD, Leleu X, Jaccard A, Faucher JL, Béné MC, Feuillard J; for the GEIL (Groupe d'Etude Immunologique des Leucémies) Study Group.

Cytometry B Clin Cytom. 2011. 80B(3):176-185.
http://www.ncbi.nlm.nih.gov/pubmed/21520405

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly

H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators.

Lancet Oncol. 2011. 12(5):460-8
http://www.ncbi.nlm.nih.gov/pubmed/21715006

New insights in the treatment of myeloma with renal failure.

Moumas E, Hanf W, Desport E, Abraham J, Delbès S, Debiais C, Lacotte-Thierry L, Touchard G, Jaccard A, Fermand JP, Bridoux F.

Nephrol Ther. 2011 Apr 22.

FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.

Desterke C, Bilhou-Nabéra C, Guerton B, Martinaud C, Tonetti C, Clay D, Guglielmelli P, Vannucchi A, Bordessoule D, Hasselbalch H, Dupriez B, Benzoubir N, Bourgeade MF, Pierre-Louis O, Lazar V, Vainchenker W, Bennaceur-Griscelli A, Gisslinger H, Giraudier S, Le Bousse-Kerdilès MC; French Intergroup of Myeloproliferative Disorders,; French INSERM; European EUMNET Networks on Myelofibrosis.

Cancer Res. 2011. 71(8):2901-15.
http://www.ncbi.nlm.nih.gov/pubmed/21487043

Current treatment of AL amyloidosis.

Desport E, Moumas E, Abraham J, Delbès S, Lacotte-Thierry L, Touchard G, Fermand JP, Bridoux F, Jaccard A.

Nephrol Ther. 2011 Apr 14.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.

Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P.

Leukemia. 2011 Apr 5.

Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool.

Loustaud-Ratti VR, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Fauchais AL, Carrier P, Lefebvre A, Bordessoule D, Vidal E, Sautereau D, Jaccard A.

Amyloid. 2011. 18(1):19-24.
http://www.ncbi.nlm.nih.gov/pubmed/21219116

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup.

Blood. 2011. 117(6):1834-9.
http://www.ncbi.nlm.nih.gov/pubmed/21123825

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhédin N, Delannoy A, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Haematologica. 2011. 96(2):245-52.
http://www.ncbi.nlm.nih.gov/pubmed/20971822

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM).

Blood. 2011. 117(2):403-11.
http://www.ncbi.nlm.nih.gov/pubmed/20940414

Le consentement éclairé est-il un leurre ? Le point de vue du médecin clinicien.

Bordessoule D, Trarieux S, Moreau S.

La finalité de la recherche médicale : vers un arraisonnement de l’être humain. Les carnets de l’espace éthique de Bretagne Occidentale n°3 (Ed Sauramps Médical). p149-187.

Voir l'article

Remerciements pour participation comme centre investigateur

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P; on behalf of the Groupe Francophone des Myelodysplasies (GFM).

 

Leuk Res. 2011 Dec 15.
http://www.ncbi.nlm.nih.gov/pubmed/22177456

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

Boissel N, Jourdan E, Pigneux A, Blanchet O, Renneville A, Recher C, Raffoux E, Cornillet-Lefebvre P,  Cayuela JM, Delaunay J,  Delabesse E, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Kammoun L, Randriamalala E, Fegueux N, Lecerf T, Béné MC, Preudhomme C, Mohamed H, Dombret H and Ifrah N.
Blood (ASH Annual Meeting Abstracts). 2011; 118: 2608.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte.

Lancet. 2011. 378(9806):1858-67.
http://www.ncbi.nlm.nih.gov/pubmed/22118442

EOSTA: An Observational Study on the Compliance and Quality of Life (QoL) of Chronic Myeloid Leukemia (CML) Patients Treated with Second Line Nilotinib (Tasigna®): Interim Results At 6 Months of Follow-up,

Rea D, Maloisel F, Huguet F, Okada H, Bourdeix I, Nicolini FE, Tulliez M and Etienne G.
Blood (ASH Annual Meeting Abstracts). 2011; 118: 37

Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

Boissel N, Jourdan E, Pigneux A, Blanchet O, Renneville A, Recher C, Raffoux E, Cornillet-Lefebvre P,  Cayuela JM, Delaunay J,  Delabesse E, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Kammoun L, Randriamalala E, Fegueux N, Lecerf T, Béné MC, Preudhomme C, Mohamed H, Dombret H and Ifrah N.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 2608.

The fox (France Observational Xagrid) study : what is the optimum method for introducing anagrelide when firts-line essential thrombocythaemia therapy fails ?

Rey J, Viallard JF, Keddad K, Kiladjian JJ.
6ème Congrès International sur les SMP et les MDS. New York, 3-4/11/2011

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.

Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators.

Eur J Haematol. 2011. 87(4):338-48.
http://www.ncbi.nlm.nih.gov/pubmed/21649735

Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype.

Micol R, Ben Slama L, Suarez F, Le Mignot L, Beauté J, Mahlaoui N, Dubois d'Enghien C, Laugé A, Hall J, Couturier J, Vallée L, Delobel B, Rivier F, Nguyen K, Billette de Villemeur T, Stephan JL, Bordigoni P, Bertrand Y, Aladjidi N, Pedespan JM, Thomas C, Pellier I, Koenig M, Hermine O, Picard C, Moshous D, Neven B, Lanternier F, Blanche S, Tardieu M, Debré M, Fischer A, Stoppa-Lyonnet D; CEREDIH Network Investigators.

J Allergy Clin Immunol. 2011. 128(2):382-9.e1.
http://www.ncbi.nlm.nih.gov/pubmed/21665257

FCGR3A polymorphism does not significantly affect response and outcome of folliculat lymphoma patients treated int the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation.

Ghesquieres H, Seymour J, Offner F, Feugier P, Brice P, Haioun C, Casasnovas O, Catalano J, Jardin F, Xerri L, G. Salles G.

Ann Oncol. 2011. 22 (suppl 4): iv87-iv88
11ème congrès ICML Lugano, juin 2011.

Pattern of infections observed during the maintenance phase in the PRIMA study.

Bouteloup M, Seymour J, Feugier P, Offner F, Lopez-Guillermo A, Bouabdallah R, Pedersen L, Brice P Belada D, Salles G.

Ann Oncol. 2011. 22 (suppl 4): iv88-iv89
11ème congrès ICML Lugano, juin 2011.

Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study.

Morschhause F, Seymour J, Feugier P, Offner F, Lopez-Guillermo A, Bouabdallah R,  Pedersen L, Brice P, Belada D, Xerri L, Salles G.

Ann Oncol. 2011. 22 (suppl 4): iv88-iv89
11ème congrès ICML Lugano, juin 2011.

Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency.

Vince N, Boutboul D, Mouillot G, Just N, Peralta M, Casanova JL, Conley ME, Bories JC, Oksenhendler E, Malphettes M, Fieschi C; DEFI Study Group.

J Allergy Clin Immunol. 2011. 127(2):538-541.e1-5.

http://www.ncbi.nlm.nih.gov/pubmed/21159371

Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study.

Boileau J, Mouillot G, Gérard L, Carmagnat M, Rabian C, Oksenhendler E, Pasquali JL, Korganow AS; DEFI Study Group.

J Autoimmun. 2011. 36(1):25-32.
http://www.ncbi.nlm.nih.gov/pubmed/21075598

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.

Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG).

Blood. 2011. 117(6):1817-21.
http://www.ncbi.nlm.nih.gov/pubmed/21139079

Communications orales et posters dans les congrès nationaux ou internationaux

Efficacy of Bortezomib/Cyclophosphamide/Dexamethasone (VCD) Chemotherapy In Naive Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III)

Jaccard A, Roussel M, Banos A, Lavergne D, Ninet J, Arnulf B, Bordessoule D, Bridoux F and Fermand JP.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 5126

Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65–70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM,

Delmer A, Tournilhac O, Leprêtre S, Cazin B, Feugier P, Dreyfus B, Mahe B, Leporrier M, Michallet AS, Jaccard  A, Divine M, Levy V, Cymbalista F, and Letestu R.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 3900.

Pharmacokinetics, Efficacy and Safety of Lenalidomide (Len) in Myeloma Patients with Renal Impairment: Results From the Prospective Study "REVIR"

Bridoux F, Arnulf B, Moreau S, Moumas E, Chen N, Alakl M, Desport E, Neel V, Jaccard  A and Fermand JP.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 2934.

Clofarabine Combinations in Adults with Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): A GRAALL Report

Pigneux A, Sauvezie M, Vey N, Raffoux E, Marcais A, Huguet F, Rousselot P, Marolleau JP, Leprêtre S, Turlure P, Chevallier  P, Hunault M, Bonmati C, Cluzeau T,  Leguay T, Ifrah N and Dombret H.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 2586.

L-Asparaginase-Loaded Red Blood Cells Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph- ALL): First Results of the GRASPALL/GRAALL-SA2-2008 Study

Hunault M,  Legay T, Huguet D, Leprêtre S, Deconinck E, Ojeda Uribe M, Bonmati C, Lioure B, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lhéritier V, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Plantier I, Orsini Piocelle F,  Liens D, Godfrin Y, Ifrah N, and Dombret  H.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 2579.

Prognostic Significance of DNA Methyltransferase 3A Mutations in Cytogenetically Normal Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association

Renneville A,  Boissel N, Nibourel O, Berthon C, Helevaut  N, Gardin C, Cayuela JM, Hayette S,  Reman O, Contentin N, Bordessoule D, Pautas C, de  Botton S,  De Revel T, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H and Preudhomme C.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 2506.

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Benhamou Y,  Assie C, Boelle PY, Buffer M, Grillberger R, Malot  S, Bordessoule D,  Galicier L  Azoulay E, Rottensteiner H, Veyradier A and Coppo P.
Blood (ASH Annual Meeting Abstracts), 2011; 118 : 2229.

CD68+ Tumor-Associated Macrophages Predict Unfavorable Treatment Outcomes in Classic Hodgkin's Lymphoma in Correlation with Early FDG-PET Assessment Results

Touati T, Delage-Corre M, Monteil J, Olivrie-Gamaury A, Moreau S, Remenieras L, Gourin MP, Abraham J, Dmytruk N, Jaccard A, and Bordessoule D.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 1558.

Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne Rauzy O, Turlure P, Vey N,  Recher C, Dartigeas C, Legros L, Delaunay J, Visanica S,  Stamatoullas A, Fenaux ¨P and Ades L
Blood (ASH Annual Meeting Abstracts), 2011; 118: 972.

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Trappe R, Oertel SHK, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Heinz A, Salles GA, Morschhauser F,  Jaccard  A, Lamy T, Leithäuser M,  Anagnostopoulos I, Raphael M, Riess H and  Choquet  S.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 878.

Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial

Turlure P, Cambier N, Roussel M, Bellucci S, Zini JM, Rain JD, Rousselot P, Vainchenker W, Abdelkader L, Ghomari K, Dutel JL, Chait Y, Chevret S, Chomienne C, Cassinat B, and Kiladjian JJ.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 280.

Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA)

Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Micol JB, Thomas X, Quesnel  B, Celli-Lebras K,  Preudhomme C, Terré C, Chevret S, Michallet M, Cordonnier C, Fenaux P, Bordessoule D, Castaigne S, and Dombret H.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 253.

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, De Revel T, Gastaud L, Gardin C, Sutton L, Marolleau JP, De Botton S, Hermine O, Plantier I, Janvier M, Dupriez B, Simon M,  De Gunzburg N, Foucault-Haiat S, Contentin N, Berthon C, Fenaux P, Henry E, Rousselot P, Preudhomme C, Chevret  S and Dombret H.
Blood (ASH Annual Meeting Abstracts), 2011; 118: 6.

Mantle cell lymphoma more tha 75 : retrospective analysis of the Limousin Regional database.

Fargeas JB, Signol N, Chicaud O, Olivrie-Gamaury A, Vigneras B, Trarieux S, Gourin MP, Bordessoule D.

Geriatric Oncology : cancer in senior adults. 11th Meeting of SIOG. Novembre 2011, Paris, France.

Computerization of the geriatric limousin database of elderly patients with hematological nteworks.

Fargeas JB, Chicaud O, Picat MA, Signol N, Vigneras B, Trarieux S, Gourin MP, Bordessoule D.

Geriatric Oncology : cancer in senior adults. 11th Meeting of SIOG. Novembre 2011, Paris, France.

The Role of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In PATIENTS with POEMS SYNDROME: A Retrospective study of the MM Subcommittee of the Chronic Leukemia Working Party of the EBMT,

Cook G, Garderet L, van Biezen A,  Henseler  A, Leblond V, Rovira M, Bordessoule D, Leone G, Ossenkoppele GJ, Byrne J, Cook M, Caballero D, de Witte TM, and Curly TCM Morris
Blood (ASH Annual Meeting Abstracts), 2011; 118: 4115.

La place de l’entourage dans le parcours de soins.

Bordessoule D, Maucourant L, Moreau SRampnoux E.
28ème congrès SFPO (Atelier), Toulouse, 16-18 Nov 2011.

Apport de la sophrologie sur le vécu d’une hospitalisation par les patients.

Zygar M, Aupetit S, Rampnoux E, Maucourant L, Truffinet V, Trarieux-Signol S, Moreau S, Bordessoule D.

SFAP, Lyon, France. Juin 2011.

Un non soignant dans un comité de soins palliatifs ?

Trarieux-Signol S, Moreau S, Gourin MP, Dubosc-Marchenay N, Robin E, Bordessoule D.

SFAP, Lyon, France. Juin 2011.

Regard d’un comité de patients sur la loi dite « Léonetti »

 Trarieux-Signol S, Castanié L, Moreau S,  Gourin MP, Dubosc-Marchenay N, Bordessoule D.

SFAP, Lyon, France. Juin 2011. Communication orale - Prix du poster discuté.

Proche et accompagnement : comment redécouvrir cet inconnu, aujourd’hui incontournable ?

Moreau S.

SFAP (Table ronde), Lyon, France. Juin 2011

Mourir à la maison, un rendez-vous trop souvent manqué ?

Moreau S.

SFAP (Table ronde), Lyon, France. Juin 2011

Management and outcome of older patients with acute myeloid leukemia (AML) in first relapse : a study from the acute leukemia french association (ALFA).

Sarkozy C, Castaigne S, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Celli-Lebras K,  Preudhomme C, Terre C.
Haematologica. 2011; 96(s2), p18.
16ème congrès EHA Londres, juin 2011.

Setting-up of the FCM OGATA protocol for diagnosis of MDS example of a French experience.

Guerin E, Cecco P, Faucher JL, Couraud MJ, Gourin MP, Ouk-Martin C, Le Guyader A, Trimoreau F, Bordessoule D, Feuillard J.
Haematologica. 2011; 96(s2), p515.
16ème congrès EHA Londres, juin 2011.

18-fluoro-deoxyglucose position emission tomography as tool to evaluate and monitor disseminated fungal infections in immunocompromized patients

Penot A, Abraham J,  Kao V, Girault S, Turlure P, Bouteille B, Monteil J, Bordessoule D.

The European Group for Blood and Bone Marrow Transplantation, Paris, France, 3-6 April 2011.

The role of high-dose chemotherapy and autologous stem cell transplantation in patients with poems syndrome: a retrospective study of the MM subcommittee of the Chronic Leukaemia Working Party of the EBMT

Cook G, Garderet L, van Biezen A, LeBlond V, Rovira M, Bordessoule D, Leone G,  Ossenkoppele S, Byrne J, de Witte T, Morris C.NOn behalf of the MM subcommittee of the Chronic Leukaemia Working Party of the EBMT.

The European Group for Blood and Bone Marrow Transplantation, Paris, France, 3-6 April 2011.

Autologous haematopoietic stem cell transplantation in elderly patients with lymphoma: French Society of Bone Marrow Graft Transplantation and Cellular Therapy experience

Hermet E, Cabrespine-Faugeras A, Garnier A, Tempescul A, Bouabdallah R, Vilque JP,  Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Gratecos N, Choufi B, Drenou B, Rubio MT, Bilger K, J.O. Bay on behalf of SFGM-TC.

The European Group for Blood and Bone Marrow Transplantation, Paris, France, 3-6 April 2011.

Allogeneic BMT patient education and body temperature monitoring after hospital transplantation stage

Tardieu L, Granet C, Aubert K, Malissein E, Guillout J, Robin E, Girault S, Turlure P,. Bordessoule D.

The European Group for Blood and Bone Marrow Transplantation, Paris, France, 3-6 April 2011.

Traitement des lymphomes du manteau des sujets âgés par de la cytarabine en sous-cutané : à propos de 3 cas.

Gourin MP, Abraham J, Trimoreau F, Penot A, Moreau S, Touati M, Olivrie-Gamaury A, Delage-Corre M, Feuillard J, Bordessoule D, Jaccard A.

Hématologie, Mars 2011 (suppl 1) ; 17: 80 [05-33]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Chimiothérapie associant cyclophosphamide-doxorubicine-oncovin-dexamethasone dans les lymphomes T.

Kennel C, Jaccard A, Olivrie A, Bordessoule D, Gourin MP, Trimoreau F, Remenerias L, Moreau S, Girault S, Dmytruk N, Abraham J.

Hématologie, Mars 2011 (suppl 1) ; 17: 99 [05-64]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Le trioxyde d’arsenic (ATO) dans le traitement de consolidation des LAP : analyse préliminaire d’un essai randomisé (APL 2006) du groupe Franco-Belgo-Suisse des LAP.

Ades L, Raffoux E, Chevret S, Pigneux A, Thomas X, Bordessoule D, Vey N, Guerci-Bresler A, Recher C, Lamy T, Dombret H, Fenaux P.

Hématologie, Mars 2011 (suppl 1) ; 17: 129 [07-14]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Devenir des LAM en première rechute chez les patients âgés de plus de 50 ans : analyse des protocoles ALFA.

Sarkozy C, Castaigne S, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Celli-Lebras K, Preudhomme C, Terré C, Gardin C, Dombret H.

Hématologie, Mars 2011 (suppl 1) ; 17: 132 [07-18]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Efficacité du protocole pédiatrique FRALLE-2000BT chez des adolescents et jeunes adultes (AJA, 15-29 ans) atteints de leucémie aiguë lymphoblastique (LAL) et traités dans des services d’hématologie adulte.

Cluzeau T, Dhedin N, Huguet F, Maury S, Lamy T, Guillerm G, Delannoy A, Turlure P, Vey N, Baruchel A, Dombret H, Boissel N.

Hématologie, Mars 2011 (suppl 1) ; 17: 133 [07-20]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

LAP secondaire (sLAP). Analyse prospective des facteurs étiologiques de cas récents et comparaison avec les LAP de novo.

Cereja S, Chevret S, Raffoux E, Beaumont M, Pigneux A, Thomas X, Bordessoule D, Vey N, Guerci A, Degos L, Dombret H, Fenaux P, Adès L.

Hématologie, 2011 (suppl 1) ; 17: 134 [07-21]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Risque d’évolution en LAM chez les patients atteints de SMD à faible risque avec délétion 5q traités avec ou sans lénalidomide : une étude du groupe francophone des SMD.

Adès L, Le Bras F, Sébert M, Bouscary D, Lamy T, Dryefus F, Delaunay J, Turlure P, Chevret S, Fenaux P.

Hématologie, Mars 2011 (suppl 1) ; 17: 172 [09-10]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Un traitement immunosuppresseur (TIS) devrait-il être utilisé plus fréquemment dans les SMD à faible risque ?

Cereja S, Bréchignac S, Adès L, Braun T, Sapena R, Beyne-Rauzy O, Vey N, Dombret H, Bordessoule D, Dreyfus F, Fenaux P, Gardin C.

Hématologie, Mars 2011 (suppl 1) ; 17: 179 [09-20]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Développement et validation d’un modèle prédictif de décès dans le purpura thrombotique trombocytopénique acquis idiopathique.

Benhamou Y, Assié C, Boelle P, Buffet M, Bordessoule D, Bonmarchand G, Galicier L, Azoulay E, Veyradier A, Coppo P.

Hématologie, Mars 2011 (suppl 1) ; 17: 225 [12-37]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Evaluation de la pratique de cytologie et de cytométrie de flux pour le diagnostic des adénopathies au CHU de Limoges.

Olombel G, Guérin E, Delage-Corre E, Bordessoule D, Jaccard A, Labrousse F, Feuillard J, Trimoreau F.

Hématologie, Mars 2011 (suppl 1) ; 17: 257 [13-23]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Pour une appropriation de la loi dite « Léonetti » au sein d’un service clinique d’hématologie clinique.

Trarieux-Signol S, Moreau S, Gourin MP, Rampnoux E, Guillout J, Bordessoule D.

Hématologie, Mars 2011 (suppl 1) ; 17: 267 [14-01] - Communication orale
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Chimiothérapie injectable à domicile pour les patients atteints d’hémopathie maligne : expérience du réseau Hématolim.

Touati M, Lefort S, Réménieras L, Moreau S, Vergnenegre F, Abouelfadel M, Lagarde A, Daulange A, Lepetit AL, Gatard V, Laffetas MC, Bordessoule D.

Hématologie, Mars 2011 (suppl 1) ; 17: 267 [14-02] - Communication orale
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

L’infirmière de recherche clinique (IDE-RC), partenaire indispensable de la recherche en milieu hospitalier. Expérience au sein d’un service d’hématologie.

Tisseuil C, Tardieu L, Guillout J, Philippon C, Bompart F, Gourin MP, Bordessoule D.

Hématologie, Mars 2011 (suppl 1) ; 17: 269 [14-05]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Impact et limites d’une équipe mobile de recherche clinique (EMRC) dans des centres hospitaliers périphériques (CHU) d’une région rurale.

Gourin MP, Simeone JB, Lefort S, Devesa D, Fargeas JB, Penot A, Touati M, Bordessoule D.

Hématologie, Mars 2011 (suppl 1) ; 17: 270 [14-06]
Congrès 2011 de la Société Française d’Hématologie. Paris, France.

Impact of PEG-interferon-alpha-2A therapy on the evolution of JAK2 and TET2 mutated clones in polycythemia vera.

Kiladjian JJ, Lesteven E, Massé A, Cassinat B, Turlure P, Bellucci S, Delhommeau F.
Haematologica. 2011; 96(s2), p445.
16ème congrès EHA Londres, juin 2011.